Your new post is loading...
The longevity and biotechnology industries are focusing on aging in a big way, and it’s beginning to show.
The fields of Artificial Intelligence (AI) and regenerative medicine are putting their money on combating aging and age-related diseases, and the benefits are likely to be immense. While biotechnology and AI are relatively new concepts, the announcements of funding and collaboration yesterday by and between three companies are bringing those concepts that much closer to the forefront of medicine.
Insilico Medicine, a Baltimore-based next-generation AI company specializing in the application of deep learning for target identification, drug discovery and aging research, yesterday announced a collaboration agreement with WuXi AppTec, a leading global contract research outsourcing provider based in Shanghai, China, serving the pharmaceutical, biotech, and medical device industries.
“It's a big step not only for Insilico Medicine but for AI and the pharmaceutical industries,” said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc. He said under terms of the agreement, WuXi AppTec will partner with Insilico to test the company’s newly discovered molecules developed to combat the aging process as well as age-related diseases.
At the same time, AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc.—which is focused on prolonging healthspan through an understanding of the fundamental mechanisms of human aging—announced yesterday that it has closed on a $5 million equity financing deal, through the sale of two million AgeX common shares to Juvenescence Ltd. BioTime now owns approximately 80.6% of AgeX’s outstanding shares, and Juvenescence and its principals own approximately 7%.
Via Dominique Godefroy
